Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Average PT from Analysts

by · The Markets Daily

Moderna, Inc. (NASDAQ:MRNAGet Free Report) has earned an average rating of “Hold” from the twenty-two research firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, twelve have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $78.83.

MRNA has been the topic of several recent analyst reports. The Goldman Sachs Group dropped their price target on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Jefferies Financial Group cut their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a research note on Thursday, September 19th. UBS Group reduced their target price on Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $69.00 price target (down from $115.00) on shares of Moderna in a research note on Monday, November 18th.

View Our Latest Report on Moderna

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last 90 days. 15.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Moderna

A number of large investors have recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Moderna during the 2nd quarter valued at approximately $26,000. Plato Investment Management Ltd increased its position in Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock worth $49,000 after buying an additional 288 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Moderna by 365.6% in the third quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after buying an additional 574 shares during the period. Larson Financial Group LLC lifted its position in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after buying an additional 317 shares during the last quarter. Finally, Rakuten Securities Inc. grew its stake in shares of Moderna by 477.3% during the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock worth $63,000 after acquiring an additional 778 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 2.1 %

MRNA opened at $42.25 on Tuesday. The stock has a market cap of $16.26 billion, a PE ratio of -7.26 and a beta of 1.60. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a fifty day moving average of $42.52 and a 200-day moving average of $69.36.

Moderna (NASDAQ:MRNAGet Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. During the same period last year, the company posted ($1.39) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, sell-side analysts predict that Moderna will post -9.3 EPS for the current year.

Moderna Company Profile

(Get Free Report

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

Further Reading